STOCK TITAN

Xtant Medical Holdings, Inc. - XTNT STOCK NEWS

Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a leader in the field of regenerative medicine and surgical solutions for spinal disorders. The company designs, develops, and markets a comprehensive range of orthobiologics and spinal implant systems to aid spinal fusion in complex spine, deformity, and degenerative procedures. Their offerings are widely utilized by orthopedic spine surgeons and neurosurgeons for treating various spinal disorders across cervical, thoracolumbar, and interbody regions.

Xtant Medical's product portfolio includes notable biomaterial products such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the 3Demin line. These products are essential for promoting bone healing, and their applications extend to orthopedic disorders and cranial, foot, and ankle surgeries. The company's innovative solutions are distributed in both domestic and international markets, making a significant impact on global neurological and orthopedic surgery markets.

In recent developments, Xtant Medical has successfully raised its 2023 annual revenue guidance to $88 million - $91 million. Furthermore, the company has projected its full-year 2024 revenue guidance between $112 million - $116 million, signifying strong growth and operational efficiency. The financial results for the first quarter of 2024 were impressive, with total revenue reaching $27.9 million, an increase of 55% compared to the previous year. This growth was driven by strategic acquisitions, increased independent agent sales, and additional product sales.

Xtant Medical is dedicated to honoring the gift of donation, enabling patients to live full and complete lives. The team at Xtant is composed of dedicated and talented individuals who operate with the highest integrity to serve their customers. The company's mission and values are reflected in their continuous innovation and commitment to providing high-quality medical solutions.

Rhea-AI Summary
Xtant Medical Holdings, Inc. (XTNT) raises 2023 Annual Revenue Guidance to $88 Million - $91 Million, reports record third quarter revenue of $25 million, an 18% organic growth, and a 73% year-over-year increase. Gross margin for Q3 2023 was 61.3% and net income totaled $9.2 million. The company also plans to host a conference call to discuss the financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
Rhea-AI Summary
Xtant Medical Holdings, Inc. will release its financial results for Q3 2023 on November 9, 2023. The company is a global medical technology company focused on surgical solutions for spinal disorders. President and CEO Sean Browne, and CFO Scott Neils, will host a conference call at 9:00 AM ET on the same day to review the results. The conference call details are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
-
Rhea-AI Summary
Xtant Medical Holdings, Inc. has acquired the nanOss production operations from RTI Surgical, Inc. for $2 million in cash plus contingent payments. The acquisition includes assets and inventory used in RTI's synthetic bone graft business and the lease for the nanOss production facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
Rhea-AI Summary
Xtant Medical Holdings to exhibit orthobiologics and spinal fixation products at NASS 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
-
Rhea-AI Summary
Xtant Medical Holdings has completed the acquisition of certain assets and liabilities related to the biologics and spinal fixation offerings of Surgalign Holdings. The all-cash transaction was worth $5 million, plus assumed liabilities. Xtant Medical aims to integrate this business with its current offerings to maximize its potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.9%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
Rhea-AI Summary
Xtant Medical Holdings, Inc. has entered into a securities purchase agreement to sell 20,000,000 shares of its common stock at $0.75 per share, resulting in gross proceeds of $15 million. The net proceeds will be used for working capital and other general corporate purposes. The private placement is expected to close on July 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
none

FAQ

What is the current stock price of Xtant Medical Holdings (XTNT)?

The current stock price of Xtant Medical Holdings (XTNT) is $0.36 as of December 20, 2024.

What is the market cap of Xtant Medical Holdings (XTNT)?

The market cap of Xtant Medical Holdings (XTNT) is approximately 49.1M.

What does Xtant Medical Holdings, Inc. specialize in?

Xtant Medical specializes in developing, manufacturing, and marketing regenerative medicine products and medical devices, particularly for spinal fusion and orthopedic surgery.

Which products are part of Xtant Medical's portfolio?

Their product portfolio includes OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the 3Demin line, among other allografts.

What are the recent financial achievements of Xtant Medical?

Xtant Medical raised its 2023 annual revenue guidance to $88 million - $91 million and established full-year 2024 revenue projections of $112 million - $116 million.

Who are the primary users of Xtant Medical's products?

Orthopedic spine surgeons and neurosurgeons mainly use Xtant Medical's products for treating various spinal disorders.

What recent business highlights has Xtant Medical reported?

In Q1 2024, Xtant Medical reported a 55% revenue growth, achieving a total revenue of $27.9 million driven by acquisitions and increased product sales.

Where can I find more information about Xtant Medical?

For further details, you can visit their official website at https://xtantmedical.com.

How does Xtant Medical contribute to patient care?

Xtant Medical is committed to honoring the gift of donation, helping patients live full lives through innovative medical solutions.

What are Xtant Medical's core competencies?

Xtant Medical has core competencies in both biologic and non-biologic surgical technologies, enabling them to compete in global neurological and orthopedic surgery markets.

How can I contact Xtant Medical for investor relations?

You can contact Brett Maas, Managing Partner at Hayden IR, via email at brett@haydenir.com or phone at (646) 536-7331.

What is the mission of Xtant Medical?

Xtant Medical's mission is to honor the gift of donation, helping patients live full and complete lives through advanced surgical solutions.

Xtant Medical Holdings, Inc.

NYSE:XTNT

XTNT Rankings

XTNT Stock Data

49.13M
55.14M
7.83%
65.12%
0.14%
Medical Devices
Biological Products, (no Disgnostic Substances)
Link
United States of America
BELGRADE